Explore how digital solutions help streamline mRNA manufacturing by reducing costs, improving efficiency, and supporting sustainability by creating paperless processes for emerging therapeutics.
- Navigating The CGT Landscape: Key Takeaways From The FDA's New FAQ
- Trends In Proposed Laws Aimed At Drug Patents
- Tackling The Pharmacovigilance Crunch At The Local Level
- Antibodies 2025: Venerable & Naked Or Complex & Multi-Specific?
- A Father's Perspective On The Rare Pediatric Disease PRV Program
- A Realistic Look At What RFK Jr. Could Mean For FDA
- Inside Interius' Global Regulatory Strategy
- The Bond Factor: Connecting For Success In Life Sciences
COMPANIES TO WATCH
-
![Amy Burroughs_Terns Pharmaceuticals]( "Companies To Watch: Terns Pharmaceuticals")
Companies To Watch: Terns PharmaceuticalsTerns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.
-
![Dr-Stella-Sarraf_Spinogenix]( "Companies To Watch: Spinogenix")
Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
-
![Greg_Kunst]( "Companies To Watch: Aurion Biotech")
Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.
-
![Mark Litton]( "Companies To Watch: Athira Pharma")
Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.
WHERE ARE THEY NOW
-
![Teva Cover]( "Where Are They Now? Teva Pharmaceuticals")
Where Are They Now? Teva PharmaceuticalsTeva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.
-
![Ironwood Cover_2016]( "Where Are They Now? Ironwood Pharmaceuticals")
Where Are They Now? Ironwood PharmaceuticalsIronwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
-
![Steven Kelly_300CMYK]( "Where Are They Now? Carisma Therapeutics")
Where Are They Now? Carisma TherapeuticsIn three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original CAR-Macrophage candidate, in favor of CAR-Monocyte therapies. Carisma expects to release CT-0525 Phase 1 data by the end of 2024.
NEWSLETTER ARCHIVE
- 01.20.25 -- Unlocking The Potential Of AI In Pharma
- 01.17.25 -- Consider The Location When Growing Your Life Science Business
- 01.15.25 -- Inside Interius' Global Regulatory Strategy
- 01.15.25 -- Revolutionizing Formulations: Explore Cutting-Edge Nanotechnology & Drug Delivery Solutions
- 01.13.25 -- Biotech Story Time With Tal Zaks, M.D.
SPOTLIGHT
Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions about what a second Trump administration could mean for biopharmaceutical IP and drug patents.
